These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 18822336

  • 1. Foot-and-mouth disease vaccine potency testing: the influence of serotype, type of adjuvant, valency, fractionation method, and virus culture on the dose-response curve in cattle.
    Jamal SM, Bouma A, van den Broek J, Stegeman A, Chénard G, Dekker A.
    Vaccine; 2008 Nov 25; 26(50):6317-21. PubMed ID: 18822336
    [Abstract] [Full Text] [Related]

  • 2. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus.
    Brehm KE, Kumar N, Thulke HH, Haas B.
    Vaccine; 2008 Mar 20; 26(13):1681-7. PubMed ID: 18313814
    [Abstract] [Full Text] [Related]

  • 3. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
    Grubman MJ.
    Biologicals; 2005 Dec 20; 33(4):227-34. PubMed ID: 16289996
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cedivac-FMD can be used according to a marker vaccine principle.
    Chénard G, Selman P, Dekker A.
    Vet Microbiol; 2008 Apr 01; 128(1-2):65-71. PubMed ID: 18035508
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle.
    Cox SJ, Voyce C, Parida S, Reid SM, Hamblin PA, Hutchings G, Paton DJ, Barnett PV.
    Vaccine; 2006 Apr 12; 24(16):3184-90. PubMed ID: 16488060
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion.
    Fowler VL, Knowles NJ, Paton DJ, Barnett PV.
    Vaccine; 2010 Apr 26; 28(19):3428-34. PubMed ID: 20199761
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dose-response evaluation of a genetically engineered foot-and-mouth disease virus polypeptide immunogen in cattle.
    McKercher PD, Moore DM, Morgan DO, Robertson BH, Callis JJ, Kleid DG, Shire SJ, Yansura DG, Dowbenko D, Small B.
    Am J Vet Res; 1985 Mar 26; 46(3):587-90. PubMed ID: 2986495
    [Abstract] [Full Text] [Related]

  • 13. Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine.
    Barrera J, Schutta C, Pisano M, Grubman MJ, Brake DA, Miller T, Kamicker BJ, Olutunmbi F, Ettyreddy D, Brough DE, Butman BT, Neilan JG.
    Vaccine; 2018 Feb 14; 36(8):1078-1084. PubMed ID: 29358056
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.